Lilly Eli & Co - Net Worth and Insider Trading

Lilly Eli & Co Net Worth

The estimated net worth of Lilly Eli & Co is at least $1.4 Billion dollars as of 2024-05-05. Lilly Eli & Co is the 10% Owner of United Therapeutics Corp and owns about 5,251,394 shares of United Therapeutics Corp (UTHR) stock worth over $1.4 Billion. Lilly Eli & Co is the 10% Owner of Zymeworks Inc and owns about 2,898,647 shares of Zymeworks Inc (ZYME) stock worth over $27 Million. Lilly Eli & Co is also the 10% Owner of Spyre Therapeutics Inc and owns about 102,742 shares of Spyre Therapeutics Inc (SYRE) stock worth over $4 Million. Besides these, Lilly Eli & Co also holds Sigilon Therapeutics Inc (SGTX) . Details can be seen in Lilly Eli & Co's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Lilly Eli & Co has not made any transactions after 2023-08-11 and currently still holds the listed stock(s).

Transaction Summary of Lilly Eli & Co

Lilly Eli & Co Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Lilly Eli & Co owns 14 companies in total, including Avidity Biosciences Inc (RNA) , Dermira Inc (DERM) , and Elanco Animal Health Inc (ELAN) among others .

Click here to see the complete history of Lilly Eli & Co’s form 4 insider trades.

Insider Ownership Summary of Lilly Eli & Co

Ticker	Comapny	Transaction Date	Type of Owner
RNA	Avidity Biosciences Inc	2020-06-11	10 percent owner
DERM	Dermira Inc	2020-02-20	10 percent owner
ELAN	Elanco Animal Health Inc	2019-03-11	10 percent owner
		2019-01-31	10 percent owner
		2017-11-14	10 percent owner
		2017-03-01	10 percent owner
		2016-04-12	10 percent owner
		2015-01-30	10 percent owner
		2014-11-06	10 percent owner
		2014-04-10	10 percent owner
		2011-07-06	10 percent owner
		2005-08-05	10 percent owner
		2023-08-11	10 percent owner
		2022-10-17	10 percent owner

Lilly Eli & Co Latest Holdings Summary

Lilly Eli & Co currently owns a total of 4 stocks. Among these stocks, Lilly Eli & Co owns 5,251,394 shares of United Therapeutics Corp (UTHR) as of July 6, 2011, with a value of $1.4 Billion and a weighting of 97.85%. Lilly Eli & Co owns 2,898,647 shares of Zymeworks Inc (ZYME) as of January 31, 2019, with a value of $27 Million and a weighting of 1.89%. Lilly Eli & Co also owns 102,742 shares of Spyre Therapeutics Inc (SYRE) as of April 12, 2016, with a value of $4 Million and a weighting of 0.26%. The other 1 stocks Sigilon Therapeutics Inc (SGTX) have a combined weighting of 0% among all his current holdings.

Latest Holdings of Lilly Eli & Co

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
UTHR	United Therapeutics Corp	2011-07-06	5,251,394	262.40	1,377,965,786
ZYME	Zymeworks Inc	2019-01-31	2,898,647	9.20	26,667,552
SYRE	Spyre Therapeutics Inc	2016-04-12	102,742	35.78	3,676,109
SGTX	Sigilon Therapeutics Inc	2023-08-11	100	22.47	2,247

Holding Weightings of Lilly Eli & Co

Lilly Eli & Co Form 4 Trading Tracker

According to the SEC Form 4 filings, Lilly Eli & Co has made a total of 0 transactions in United Therapeutics Corp (UTHR) over the past 5 years. The most-recent trade in United Therapeutics Corp is the sale of 49,103 shares on July 6, 2011, which brought Lilly Eli & Co around $3 Million.

According to the SEC Form 4 filings, Lilly Eli & Co has made a total of 0 transactions in Zymeworks Inc (ZYME) over the past 5 years. The most-recent trade in Zymeworks Inc is the sale of 250,000 shares on January 31, 2019, which brought Lilly Eli & Co around $4 Million.

According to the SEC Form 4 filings, Lilly Eli & Co has made a total of 0 transactions in Spyre Therapeutics Inc (SYRE) over the past 5 years. The most-recent trade in Spyre Therapeutics Inc is the acquisition of 20,000 shares on April 12, 2016, which cost Lilly Eli & Co around $5 Million.

More details on Lilly Eli & Co's insider transactions can be found in the Insider Trading History of Lilly Eli & Co table.

Insider Trading History of Lilly Eli & Co

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Lilly Eli & Co Trading Performance

GuruFocus tracks the stock performance after each of Lilly Eli & Co's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Lilly Eli & Co is -39.17%. GuruFocus also compares Lilly Eli & Co's trading performance to market benchmark return within the same time period. The performance of stocks bought by Lilly Eli & Co within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Lilly Eli & Co's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Lilly Eli & Co

Average Return

Average return per transaction

Outperforming Transactions

0 out of 2 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-5.76
Relative Return to S&P 500(%)	-7.47

Lilly Eli & Co Ownership Network

Ownership Network List of Lilly Eli & Co

No Data

Ownership Network Relation of Lilly Eli & Co

Lilly Eli & Co Owned Company Details

What does Avidity Biosciences Inc do?

Who are the key executives at Avidity Biosciences Inc?

Lilly Eli & Co is the 10 percent owner of Avidity Biosciences Inc. Other key executives at Avidity Biosciences Inc include Chief Scientific Officer Arthur A Levin , director & President and CEO Sarah Boyce , and Chief Financial Officer Michael F Maclean .

Avidity Biosciences Inc (RNA) Insider Trades Summary

Over the past 18 months, Lilly Eli & Co made no insider transaction in Avidity Biosciences Inc (RNA). Other recent insider transactions involving Avidity Biosciences Inc (RNA) include a net sale of 119,600 shares made by Arthur A Levin , a net sale of 195,092 shares made by Sarah Boyce , and a net sale of 41,616 shares made by Michael F Maclean .

In summary, during the past 3 months, insiders sold 237,641 shares of Avidity Biosciences Inc (RNA) in total and bought 0 shares, with a net sale of 237,641 shares. During the past 18 months, 362,502 shares of Avidity Biosciences Inc (RNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 362,502 shares.

Avidity Biosciences Inc (RNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avidity Biosciences Inc Insider Transactions

No Available Data

What does Dermira Inc do?

Who are the key executives at Dermira Inc?

Lilly Eli & Co is the 10 percent owner of Dermira Inc. Other key executives at Dermira Inc include director & Chief Medical Officer Eugene A Bauer , director & CEO & Chairman of the Board Thomas G Wiggans , and CFO Andrew Guggenhime .

Dermira Inc (DERM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Dermira Inc (DERM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dermira Inc (DERM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Dermira Inc (DERM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dermira Inc Insider Transactions

No Available Data

What does Elanco Animal Health Inc do?

Who are the key executives at Elanco Animal Health Inc?

Lilly Eli & Co is the 10 percent owner of Elanco Animal Health Inc. Other key executives at Elanco Animal Health Inc include EVP & MANUFACTURING AND QUALITY Grace Mcardle , See remarks Timothy J Bettington , and director & Pres. & Chief Executive Officer Jeffrey N Simmons .

Elanco Animal Health Inc (ELAN) Insider Trades Summary

Over the past 18 months, Lilly Eli & Co made no insider transaction in Elanco Animal Health Inc (ELAN). Other recent insider transactions involving Elanco Animal Health Inc (ELAN) include a net purchase of 40,000 shares made by R David Hoover , a net purchase of 15,000 shares made by William F Doyle , and a net purchase of 15,000 shares made by Jeffrey N Simmons .

In summary, during the past 3 months, insiders sold 0 shares of Elanco Animal Health Inc (ELAN) in total and bought 38,100 shares, with a net purchase of 38,100 shares. During the past 18 months, 0 shares of Elanco Animal Health Inc (ELAN) were sold and 80,600 shares were bought by its insiders, resulting in a net purchase of 80,600 shares.

Elanco Animal Health Inc (ELAN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Elanco Animal Health Inc Insider Transactions

No Available Data

What does Zymeworks Inc do?

Who are the key executives at Zymeworks Inc?

Lilly Eli & Co is the 10 percent owner of Zymeworks Inc. Other key executives at Zymeworks Inc include director & Chair & CEO Kenneth Galbraith , SVP & Chief Financial Officer Christopher Astle , and Chief Scientific Officer Paul Andrew Moore .

Zymeworks Inc (ZYME) Insider Trades Summary

Over the past 18 months, Lilly Eli & Co made no insider transaction in Zymeworks Inc (ZYME). Other recent insider transactions involving Zymeworks Inc (ZYME) include a net purchase of 5,868,900 shares made by Ecor1 Capital, Llc , a net sale of 8,654 shares made by Christopher Astle , and a net sale of 7,425 shares made by Neil Josephson .

In summary, during the past 3 months, insiders sold 0 shares of Zymeworks Inc (ZYME) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 52,759 shares of Zymeworks Inc (ZYME) were sold and 5,868,900 shares were bought by its insiders, resulting in a net purchase of 5,816,141 shares.

Zymeworks Inc (ZYME)'s detailed insider trading history can be found in Insider Trading Tracker table.

Zymeworks Inc Insider Transactions

No Available Data

What does Leap Therapeutics Inc do?

Who are the key executives at Leap Therapeutics Inc?

Lilly Eli & Co is the 10 percent owner of Leap Therapeutics Inc. Other key executives at Leap Therapeutics Inc include Chief Scientific Officer Jason Baum , 10 percent owner Beigene, Ltd. , and VP & Head of Reg Affairs/Qual Christine Granfield .

Leap Therapeutics Inc (LPTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Leap Therapeutics Inc (LPTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Leap Therapeutics Inc (LPTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Leap Therapeutics Inc (LPTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Leap Therapeutics Inc Insider Transactions

No Available Data

What does CoLucid Pharmaceuticals Inc do?

Who are the key executives at CoLucid Pharmaceuticals Inc?

Lilly Eli & Co is the 10 percent owner of CoLucid Pharmaceuticals Inc. Other key executives at CoLucid Pharmaceuticals Inc include 10 percent owner Pappas Capital, Llc , 10 percent owner Tvm Life Science Ventures Vii L.p. , and director & 10 percent owner Luc Marengere .

CoLucid Pharmaceuticals Inc (CLCD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of CoLucid Pharmaceuticals Inc (CLCD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of CoLucid Pharmaceuticals Inc (CLCD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

CoLucid Pharmaceuticals Inc (CLCD)'s detailed insider trading history can be found in Insider Trading Tracker table.

CoLucid Pharmaceuticals Inc Insider Transactions

No Available Data

What does Spyre Therapeutics Inc do?

Who are the key executives at Spyre Therapeutics Inc?

Lilly Eli & Co is the 10 percent owner of Spyre Therapeutics Inc. Other key executives at Spyre Therapeutics Inc include Chief Financial Officer Scott L Burrows , See Remarks Heidy King-jones , and director & 10 percent owner Fairmount Healthcare Co-invest L.p. .

Spyre Therapeutics Inc (SYRE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Spyre Therapeutics Inc (SYRE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Spyre Therapeutics Inc (SYRE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Spyre Therapeutics Inc (SYRE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Spyre Therapeutics Inc Insider Transactions

No Available Data

What does Zosano Pharma Corp do?

Who are the key executives at Zosano Pharma Corp?

Lilly Eli & Co is the 10 percent owner of Zosano Pharma Corp. Other key executives at Zosano Pharma Corp include director & Chief Executive Officer Steven Lo , Chief Financial Officer Christine Matthews , and VP & Clinical Dev & Med Affairs Donald J Kellerman .

Zosano Pharma Corp (ZSANQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Zosano Pharma Corp (ZSANQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Zosano Pharma Corp (ZSANQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Zosano Pharma Corp (ZSANQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Zosano Pharma Corp Insider Transactions

No Available Data

What does Coherus BioSciences Inc do?

Who are the key executives at Coherus BioSciences Inc?

Lilly Eli & Co is the 10 percent owner of Coherus BioSciences Inc. Other key executives at Coherus BioSciences Inc include director & President and CEO Dennis M Lanfear , Chief Financial Officer Mcdavid Stilwell , and See Remarks Bryan J Mcmichael .

Coherus BioSciences Inc (CHRS) Insider Trades Summary

Over the past 18 months, Lilly Eli & Co made no insider transaction in Coherus BioSciences Inc (CHRS). Other recent insider transactions involving Coherus BioSciences Inc (CHRS) include a net sale of 223,100 shares made by Dennis M Lanfear ,

In summary, during the past 3 months, insiders sold 0 shares of Coherus BioSciences Inc (CHRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 223,100 shares of Coherus BioSciences Inc (CHRS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 223,100 shares.

Coherus BioSciences Inc (CHRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Coherus BioSciences Inc Insider Transactions

No Available Data

What does Dare Bioscience Inc do?

Who are the key executives at Dare Bioscience Inc?

Lilly Eli & Co is the 10 percent owner of Dare Bioscience Inc. Other key executives at Dare Bioscience Inc include director & Chef Executive Officer Sabrina Martucci Johnson , Chief Strategy Officer John A Fair , and Chief Financial Officer Lisa Walters-hoffert .

Dare Bioscience Inc (DARE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Dare Bioscience Inc (DARE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dare Bioscience Inc (DARE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Dare Bioscience Inc (DARE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dare Bioscience Inc Insider Transactions

No Available Data

What does United Therapeutics Corp do?

Who are the key executives at United Therapeutics Corp?

Lilly Eli & Co is the 10 percent owner of United Therapeutics Corp. Other key executives at United Therapeutics Corp include director & Chief Executive Officer Martine A Rothblatt , EVP & General Counsel Paul A Mahon , and President and COO Michael Benkowitz .

United Therapeutics Corp (UTHR) Insider Trades Summary

Over the past 18 months, Lilly Eli & Co made no insider transaction in United Therapeutics Corp (UTHR). Other recent insider transactions involving United Therapeutics Corp (UTHR) include a net sale of 1,314,885 shares made by Martine A Rothblatt , a net sale of 200,500 shares made by Paul A Mahon , and a net sale of 1,977 shares made by Nilda Mesa .

In summary, during the past 3 months, insiders sold 457,890 shares of United Therapeutics Corp (UTHR) in total and bought 0 shares, with a net sale of 457,890 shares. During the past 18 months, 1,537,402 shares of United Therapeutics Corp (UTHR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,537,402 shares.

United Therapeutics Corp (UTHR)'s detailed insider trading history can be found in Insider Trading Tracker table.

United Therapeutics Corp Insider Transactions

No Available Data

What does Ionis Pharmaceuticals Inc do?

Who are the key executives at Ionis Pharmaceuticals Inc?

Lilly Eli & Co is the 10 percent owner of Ionis Pharmaceuticals Inc. Other key executives at Ionis Pharmaceuticals Inc include EVP & Corp and Development Ops Brian Birchler , Chief Business Officer Joseph Baroldi , and director & Senior Vice President Brett P Monia .

Ionis Pharmaceuticals Inc (IONS) Insider Trades Summary

Over the past 18 months, Lilly Eli & Co made no insider transaction in Ionis Pharmaceuticals Inc (IONS). Other recent insider transactions involving Ionis Pharmaceuticals Inc (IONS) include a net sale of 183,300 shares made by Brett P Monia , a net sale of 57,263 shares made by Patrick R. O'neil , and a net sale of 67,074 shares made by C Frank Bennett .

In summary, during the past 3 months, insiders sold 5,298 shares of Ionis Pharmaceuticals Inc (IONS) in total and bought 0 shares, with a net sale of 5,298 shares. During the past 18 months, 639,101 shares of Ionis Pharmaceuticals Inc (IONS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 639,101 shares.

Ionis Pharmaceuticals Inc (IONS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ionis Pharmaceuticals Inc Insider Transactions

No Available Data

What does Sigilon Therapeutics Inc do?

Who are the key executives at Sigilon Therapeutics Inc?

Lilly Eli & Co is the 10 percent owner of Sigilon Therapeutics Inc. Other key executives at Sigilon Therapeutics Inc include 10 percent owner Shenandoah Acquisition Corp , CHIEF OF STAFF AND CLO Matthew Paul Kowalsky , and CTOO Qing Sarah Yuan .

Sigilon Therapeutics Inc (SGTX) Insider Trades Summary

Over the past 18 months, Lilly Eli & Co made 1 insider transaction in Sigilon Therapeutics Inc (SGTX) with a net purchase of 1,718,493.

In summary, during the past 3 months, insiders sold 0 shares of Sigilon Therapeutics Inc (SGTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sigilon Therapeutics Inc (SGTX) were sold and 1,718,493 shares were bought by its insiders, resulting in a net purchase of 1,718,493 shares.

Sigilon Therapeutics Inc (SGTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sigilon Therapeutics Inc Insider Transactions

No Available Data

What does Akouos Inc do?

Who are the key executives at Akouos Inc?

Lilly Eli & Co is the 10 percent owner of Akouos Inc. Other key executives at Akouos Inc include 10 percent owner Kearny Acquisition Corp , Chief Operating Officer Jennifer Anne Wellman , and Chief Financial Officer Sachiyo Minegishi .

Akouos Inc (AKUS) Insider Trades Summary

Over the past 18 months, Lilly Eli & Co made no insider transaction in Akouos Inc (AKUS). Other recent insider transactions involving Akouos Inc (AKUS) include a net purchase of 29,992,668 shares made by Kearny Acquisition Corp ,

In summary, during the past 3 months, insiders sold 0 shares of Akouos Inc (AKUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akouos Inc (AKUS) were sold and 29,992,668 shares were bought by its insiders, resulting in a net purchase of 29,992,668 shares.

Akouos Inc (AKUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Akouos Inc Insider Transactions

No Available Data

Lilly Eli & Co Mailing Address

Above is the net worth, insider trading, and ownership report for Lilly Eli & Co. You might contact Lilly Eli & Co via mailing address: Lilly Corporate Center, Drop Code 1094, Indianapolis In 46285.

Discussions on Lilly Eli & Co

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.